Product Description |
FITC-Compatible Human CD19 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Pro20-Lys291. |
Product Background |
CD19 is a B-lineage-specific transmembrane glycoprotein, the expression of which is maintained on more than 95% B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs). T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA approved for the treatment of relapsed or refractory large B-cell lymphoma. Despite the success and curative potential of CD19 CAR T cells, several reports describing disease relapse due to antigen loss are now emerging. |
Product Category |
Recombinant Protein |
Target |
FITC-Compatible CD19 |
Synonyms |
CD19; B4; CVID3; Leu-12; MGC12802 |
Accession |
|
Species |
Human |
Biotinylated |
no |
Amino Acid Range |
Pro20-Lys291 |
Molecular Weight |
The protein has a predicted MW of 60.1 kDa. Due to glycosylation, the protein migrates to 68-72 kDa based on Bis-Tris PAGE result. |
Product Tag |
C-His |
Fluorophore |
FITC |
Express System |
HEK293 |
Purity |
> 95% as determined by Bis-Tris PAGE;> 95% as determined by HPLC |
Endotoxin |
Less than 1 EU per ug by the LAL method. |
Form |
Liquid |
Shipping |
Shipped with dry ice. |
Formulation |
Supplied as 0.22 um filtered solution in PBS (pH 7.4). |
Stability And Storage |
Valid for 12 months from date of receipt when stored at -80°C.; Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
Related Products
Recently viewed